XFOR Dividend: X4 Pharmaceuticals Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

XFOR Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	33	2	0	0	0	3
Revenue Growth (YoY)	3,200%	--	--	--	-100%	--
Cost of Revenue	5	0	--	--	--	--
Gross Profit	28	1	--	--	--	--
Selling, General & Admin	51	61	35	27	24	20
Research & Development	75	81	72	61	50	41
Operating Expenses	127	143	107	88	75	62
Other Non Operating Income (Expenses)	9	2	0	-4	0	0
Pretax Income	-94	-37	-101	-93	-88	-61
Income Tax Expense	0	0	0	0	0	0
Net Income	-95	-37	-101	-96	-102	-62
Net Income Growth	494%	-63%	5%	-6%	65%	17%
Shares Outstanding (Diluted)	25.14	6.7	5.92	2.11	0.85	0.66
Shares Change (YoY)	276%	13%	180%	147%	28%	74%
EPS (Diluted)	-3.78	-5.58	-17.07	-45.53	-119.59	-92.84
EPS Growth	51%	-67%	-63%	-62%	28.99%	-33%
Free Cash Flow	-106	-138	-96	-77	-71	-60
Free Cash Flow Per Share	-4.21	-20.59	-16.19	-36.36	-82.73	-89.65
Gross Margin	84.84%	50%	--	--	--	--
Operating Margin	-296.96%	-7,050%	0%	0%	0%	-1,966.66%
Profit Margin	-287.87%	-1,850%	0%	0%	0%	-2,066.66%
Free Cash Flow Margin	-321.21%	-6,900%	0%	0%	0%	-2,000%
EBITDA	-97	-141	-107	-88	-75	-59
EBITDA Margin	-293.93%	-7,050%	0%	0%	0%	-1,966.66%
D&A For EBITDA	1	0	0	0	0	0
EBIT	-98	-141	-107	-88	-75	-59
EBIT Margin	-296.96%	-7,050%	0%	0%	0%	-1,966.66%
Effective Tax Rate	0%	0%	0%	0%	0%	0%